SCHEMBL397879

SCHEMBL397879

O=C(c1cccc(S(=O)(=O)Nc2ccccc2C(F)(F)F)c1)N1CCN2CCC[C@@H]2C1

nearest known ligand 0.79

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 4/20 0.79
LMNA P02545 4/20 0.54
HTT P42858 2/20 0.54
KMT2A Q03164 1/20 0.54
ALDH1A1 P00352 3/20 0.49
POLB P06746 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SIRT5 Q9NXA8 1/20 0.46
UBE2N P61088 1/20 0.46
USP2 O75604 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397187 1.00 CACNA1H (0.79) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL395430 0.88 CACNA1H (1.00) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL400191 0.88 CACNA1H (1.00) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL398413 0.86 CACNA1H (0.80) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL397457 0.86 CACNA1H (0.80) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL395364 0.85 CACNA1H (0.88) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL400086 0.85 CACNA1H (0.94) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL397734 0.85 CACNA1H (0.88) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL395972 0.85 CACNA1H (0.69) CACNA1HLMNAHTTKMT2AALDH1A1
SCHEMBL395925 0.85 CACNA1H (0.77) CACNA1HLMNAHTTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382191-B1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE BAHAMAS LTD (BS) 2014-11-12 EP claimed
US-20130210827-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-08-15 US claimed
US-8101614-B2 Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-01-24 US claimed
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-08-05 US claimed
EP-2382191-B1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE BAHAMAS LTD (BS) 2014-11-12 EP disclosed
US-8741899-B2 (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof ABBVIE INC. (US) 2014-06-03 US disclosed
US-20130210827-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-08-15 US disclosed
US-8101614-B2 Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-01-24 US disclosed
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210827-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS CACNA1E, RYR2, RYR1 CACNA1H 13/4885LMNA 868/4885HTT 2691/4885
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS CACNA1E, RYR2, RYR1 CACNA1H 13/4885LMNA 868/4885HTT 2691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.